DGAP-Ad-hoc: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel
BRAIN AG: New Chairman of the Management Board - Adriaan Moelker takes over from
The Supervisory Board of BRAIN AG has appointed Mr. Adriaan Moelker to the Management Board with effect from 1 February 2020 and appointed him as the future Chairman of the Board (CEO). Dr Jürgen Eck, co-founder of BRAIN, Chief Technology Officer (CTO) for around 26 years as well as CEO since 1 August 2015, will resign from the Management Board on 31 December 2019 and will leave the company by mutual agreement. Dr Eck will remain available to BRAIN as a consultant.
Adriaan Moelker has more than 20 years of professional experience in industrial biotechnology. He is currently Divisional President for Image Transfer Solutions and a member of the Flint Group Executive Management Team. Previously, the native Dutchman was CEO of AB Enzymes GmbH in Darmstadt for nine years. The Supervisory Board believes that this change in the Management Board spearheads the next development phase of BRAIN, which will focus on the consistent commercialization of the company's product and project base.
Martina Schuster, Investor Relations
B.R.A.I.N. Biotechnology Research and Information Network AG
Investor Relations Office
Information and Explanation of the Issuer to this News:
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
02-Dec-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||B.R.A.I.N. Biotechnology Research And Information Network AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||925595|
|End of Announcement||DGAP News Service|
925595 02-Dec-2019 CET/CEST